IP Library Granted Patent US 9,789,191
Granted Patent B2
US 9,789,191 · App. 14/672,337 · Granted Oct 17, 2017

Aqueous drug delivery system

Inventor: Kyle A. Reed (Manalapan, NJ)
Assignee: Solixa Technologies, Inc.
A61K47/36A23L2/52A23L27/84A61K9/0095A61K9/06A61K9/1652A61K31/167A61K31/192A61K31/4422A61K31/465A61K31/496A61K31/616A61K31/663A61K31/7048A61K47/40A61K47/48969B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,789,191
App. No.
14/672,337
Granted
Oct 17, 2017
Kind
B2
Abstract

Novel water stable pharmaceutical compositions, their liquid form oral pharmaceutical compositions and kits thereof, rehydration beverages containing these water stable pharmaceutical compositions methods of manufacture and methods of use thereof are disclosed. The novel aqueous delivery systems are useful, inter alia, as alternative pharmaceutical dosing agents to tablets, capsules and other forms of delivering medication to a mammalian host in need thereof.

Claims (41)

1. A water stable pharmaceutical gel composition comprising:

a therapeutic agent comprising guaifenesin; and

an off-flavor masking agent comprising a cyclodextrin;

in a water stable pharmaceutically acceptable gel matrix;

wherein:

the water stable pharmaceutically acceptable gel matrix comprises a non-ion-specific gel comprising gellan.

2. A water stable pharmaceutical composition of claim 1 , wherein the cyclodextrin comprises alpha-, beta-, or gamma-cyclodextrin, or a derivative or mixture thereof.

3. A water stable pharmaceutical composition of claim 2 , wherein the cyclodextrin comprises beta-cyclodextrin, or a derivative thereof.

4. A water stable pharmaceutical composition of claim 2 , wherein the cyclodextrin comprises alpha-cyclodextrin, or a derivative thereof.

5. A water stable pharmaceutical composition of claim 1 , wherein at least a portion of the cyclodextrin and at least a portion of the therapeutic agent are present in the pharmaceutical composition as a therapeutic agent:cyclodextrin complex.

6. A water stable pharmaceutical composition of claim 5 , wherein more than about 50% by weight of the therapeutic agent is present in the pharmaceutical composition as a therapeutic agent:cyclodextrin complex.

7. A water stable pharmaceutical composition of claim 1 , wherein the molar ratio of therapeutic agent to cyclodextrin is from about 1:2 to about 2:1.

8. A water stable pharmaceutical composition of claim 7 , wherein the molar ratio of therapeutic agent to cyclodextrin is from about 1:1.5 to about 1.5:1.

9. A water stable pharmaceutical composition of claim 3 , wherein the off-flavor masking agent is beta-cyclodextrin or hydroxypropyl beta-cyclodextrin.

10. A water stable pharmaceutical composition of claim 4 , wherein the off-flavor masking agent is alpha-cyclodextrin.

11. A water stable pharmaceutical gel composition according to claim 1 , wherein the therapeutic agent further comprises a cough suppressant.

12. A water stable pharmaceutical gel composition according to claim 11 , wherein the cough suppressant comprises dextromethorphan.

13. A water stable pharmaceutical gel composition according to claim 1 , wherein the therapeutic agent further comprises a decongestant.

14. A water stable pharmaceutical gel composition according to claim 13 , wherein the decongestant comprises pseudoephedrine.

15. A water stable pharmaceutical gel composition according to claim 1 , wherein the therapeutic agent further comprises a cough suppressant and a decongestant.

16. A water stable pharmaceutical gel composition according to claim 15 , wherein the cough suppressant comprises dextromethorphan.

17. A water stable pharmaceutical composition of claim 1 , wherein the gellan matrix is provided in the form of beads.

18. A water stable pharmaceutical composition of claim 17 , further comprising a bead shape retention compound.

19. A water stable pharmaceutical composition of claim 18 , wherein the shape retention compound is xanthan.

20. A liquid form oral pharmaceutical composition; comprising:

a water stable pharmaceutical composition according to claim 1 ; and

a pharmaceutically acceptable aqueous liquid medium.

21. A liquid form oral pharmaceutical composition of claim 20 , wherein at least a portion of the cyclodextrin and at least a portion of the therapeutic agent are present as a therapeutic agent:cyclodextrin complex in the pharmaceutical composition.

22. A kit, comprising:

a. the liquid form oral pharmaceutical composition of claim 20 in one or more containers; and

b. instructions for administering the liquid form oral pharmaceutical composition.

23. A kit of claim 22 , wherein the liquid form oral pharmaceutical composition in the kit container is provided as an individual dosage unit of therapeutic agent.

24. A rehydration beverage composition, comprising:

a water stable pharmaceutical composition according to claim 1 ; a pharmaceutically acceptable aqueous liquid medium; and

optionally at least one mineral or non-mineral nutritional supplement; wherein:

the aqueous medium comprises an isotonic solution.

25. A water stable pharmaceutical gel composition according to claim 13 , wherein the therapeutic agent further comprises acetaminophen.

26. A water stable pharmaceutical gel composition according to claim 16 , wherein the therapeutic agent further comprises acetaminophen.

27. A water stable pharmaceutical composition of claim 2 , wherein the cyclodextrin comprises gamma-cyclodextrin, or a derivative thereof.

28. A water stable pharmaceutical composition of claim 8 , wherein the molar ratio of therapeutic agent to cyclodextrin is from about 1:1.25 to about 1.25:1.

29. A water stable pharmaceutical composition of claim 28 , wherein the molar ratio of therapeutic agent to cyclodextrin is from about 1:1.1 to about 1.1:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: SOLIXA TECHNOLOGIES, INC.
To: NO MORE PILLS, LLC
Reel/Frame 050721/0959 →
CHANGE OF NAME Recorded Aug 19, 2016
From: BEV-RX, INC.
To: SOLIXA TECHNOLOGIES, INC.
Reel/Frame 039754/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2016
From: REED, KYLE A.
To: BEV-RX, INC.
Reel/Frame 039271/0721 →
Continuity (3)
Continuation 13231150 · Sep 13, 2011
Provisional Application 61392098 · Sep 13, 2010
Related Publication 20150209435A1 · Jul 30, 2015